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and applied to NHWS averages. Results: RLS patients, when compared to matched 
controls, reported significantly more Health Care Provider (HCP) visits (7.46 vs. 4.42, 
p< .001), Emergency Room (ER) visits (0.45 vs. 0.24, p< .001), and hospitalizations (0.24 
vs. 0.15, p< .001) than controls over the previous 6 month period. RLS patients also 
reported a significantly greater percentage of absenteeism (8.10 vs. 3.92, p< .001), 
presenteeism (26.48 vs. 15.78, p< .001), overall work productivity loss (30.09 vs. 
18.07, p< .001), and activity impairment (46.11 vs. 29.70, p< .001). RLS patients accu-
mulated more direct ($28,871 vs. $17,619, p< .001) and indirect ($10,199 vs. $6,452, 
p< .001) costs annually than controls. For all outcomes reported, an increase in RLS 
severity was significantly correlated with worse health outcomes and increased 
costs. ConClusions: This study sought to quantify the burden that RLS places 
on patients–especially with regard to health care costs—as little is known about 
the economic burden of RLS. Results demonstrate that RLS places a significant 
humanistic and economic burden on patients including loss in work productivity, 
increased health care utilization, and, as a result, greater direct and indirect costs.
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objeCtives: To assess the prevalence of needle phobia and associated clini-
cal practice patterns among patients with MS in Europe and the United States 
(US). Methods: A multicenter retrospective chart-review study of MS patients to 
collect de-identified data on diagnosis, clinical status and treatment approaches. 
Health care providers (HCPs, 95% neurologists) in UK/Germany/France/Italy/Spain 
(EU5) and US were screened for duration of practice (> = 3yrs) and patient volume 
(> = 15 MS patients/month) and recruited from a large panel to be geographically rep-
resentative in each country. Medical charts of the next 10 consecutive MS patients 
were selected by each HCP. Results: 360 HCPs abstracted chart data on 3490 eligible 
MS patients (mean age:39yrs; female:66%). Across markets, 12% (n= 425; EU5:10%; 
US:19%) of patients had needle phobia/did not want to inject. Age, gender, and 
disease severity did not differ compared to patients who did not have injection 
concerns. Among patients with injection concerns, 40% in the EU5 and 30% in the 
US were not currently on treatment, compared with 29% and 20%, respectively, who 
did not have injection concerns. Patients with injection concerns who discontinued 
treatment (13%) had been on their most recent treatment for a mean of 28mo (EU5) 
to 37mo (US). Injection-site reactions, flu-like symptoms, or other tolerability/side-
effects/safety concerns were reported as the reason for discontinuation in 43% 
(EU5) to 50% (US) of patients. Patient refusal was the most common reason that 
patients with injection concerns are not currently receiving treatment (EU5:75%, 
US:65%). Among all relapsing-remitting MS patients in their practice, HCPs noted 
26%(US)/34%(EU5) of patients requesting an oral treatment; among those, only 
20%(US)/13%(EU5) were subsequently switched to oral treatment. ConClusions: 
Needle phobia may add to the humanistic burden of MS and may lead to treatment 
discontinuation and potentially poorer treatment outcomes. Further research is 
warranted to quantify this burden and devise strategies to alleviate it.
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objeCtives: Relapsing-remitting multiple sclerosis (RRMS) patients have a vari-
ety of disease-modifying treatments available with varying risk-benefit trade-offs 
requiring engaging patients in shared decision making, and personalizing patients’ 
treatment by their willingness to accept risk for benefits. This study aimed to quan-
tify the amount of risk RRMS patients were willing to take for three levels of health 
improvement, compare if the acceptable risk varied by baseline disease severity or 
level of improvement gained, and identify predictors of risk attitude to help guide 
treatment choices. Methods: 239 RRMS patients from a neurology clinic completed 
a questionnaire about personal and disease characteristics and a computerized 
standard gamble survey that elicited their utility for current MS health states rela-
tive to improved health states with treatment. From these, patients’ acceptable risks 
of death for three levels of health improvement were calculated. Non-parametric 
statistical analyses were used to compare groups and linear regressions were run to 
identify significant predictors of risk attitude. Results: 199 patients were included 
in the final analysis after removing incomplete or incoherent responses. They were 
predominantly non-Hispanic white females. On average, RRMS patients were willing 
to take an 8.38% risk of death for an improvement in health state. The mean accept-
able risk of death for mild, moderate, and substantial improvement was 5.72%, 
8.03%, and 11.44% (p= 0.0001). Patients with current moderate-severe disease were 
willing to risk significantly more than patients with mild disease (all improve-
ment levels, p< 0.05). Significant predictors of higher risk acceptance included esti-
mated Expanded Disability Status Scale (EDSS) score and non-white ethnicity. Per 
point increase in estimated EDSS, patients were willing to accept 1-2% more risk of 
death. ConClusions: RRMS patients are willing to risk more as their disease wors-
ens and as treatment benefits gained are greater. Patient characteristics, including 
risk-benefit preferences should be used to personalize medicine to the individual.
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reasons for switching and/or non-adherence included: fever (45%), build-up of 
scar tissue from continued injections (35%), not feeling as if their medication is 
working (32%), kidney distress (26%), experiencing a relapse (19%) and insomnia 
(18%). ConClusions: We set out to learn whypatients switched from one drug 
to another, not just information that a switch occurred. The more we know about 
patients’ reasons for their behavior, the more we can actively plan and organize 
patient-centric research, development and outreach. Our results demonstrate that 
using physician-patient interaction data can add tremendous value to outcomes 
researchers and health care decision makers.
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objeCtives: Parkinson´s disease is a neurodegenerative disorder with an esti-
mated incidence of 40-50 cases per 100,00 habitants per year. The EQ-5D health-
related quality of life instrument comprises a health state classification followed 
by a health evaluation using a visual analogue scale (VAS). In this paper, we exam-
ine the correspondence between VAS scores and health state classifications for a 
mexican sample, and identify variables which contribute to determining the VAS 
scores. Methods: A mexican retrospective study of patients having Parkinson´s 
disease from the National Institute of Neurology and Neurosurgery (INNN) provided 
EQ-5D data. Information on seveirty, psychosis and socio-demographic characteris-
tics had been collected using other instruments. A stepwise linear regression model 
was fitted, in which the choice of predictive variables is carried out by an automatic 
procedure. VAS score was the dependent variable, independent variables comprised 
EQ-5D health state classifications, severity, age, psychosis and socio-demographic 
characteristics. Results: 248 mexican patients were evaluated in the model: 54% 
were male and 46% were female; also 74.2% had low severity, 18.5% had moderate 
severity and 7.3% had advanced severity; in addition, 16.5% of pacientes hadn´t 
formal education compared to 21% of patients having college or higher educa-
tion. Finally, 60.1% of patients were 60 years old or more when the retrospective 
study was performed. EQ-5D health state classifications (personal hygiene, mobil-
ity, anxiety/depression) were statistically significant fitting the model. In addition, 
VAS score was influenced also by the subject’s educational attainment (p-value< .05, 
R2= 19). Changes in VAS score were explained by changes in both EQ-5D mobility and 
anxiety. ConClusions: In this sample, EQ VAS scores were predictable from the 
EQ-5D health state classifications (personal higiene, mobility and anxiety/depres-
sion), although there also existed another variable (educational attainment) which 
contributed systematically and independently towards determining such scores.
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objeCtives: Parkinson´s disease is a neurodegenerative disorder with an estimated 
incidence of 40-50 cases per 100,00 habitants per year. The EQ-5D is a brief, multi-
attribute, preference-based health status measure. In this paper, we describe the 
development of a statistical model for generating mexican sample-based EQ-5D 
utility index for patients having Parkinson´s disease. Methods: A mexican retro-
spective study of patients having Parkinson´s disease from the National Institute 
of Neurology and Neurosurgery (INNN) provided EQ-5D health state classification. 
Respondents valued EQ-5D health states using the visual analogue score (VAS) 
method. A linear regression model was fitted, VAS score was the dependent vari-
able and the independent variables comprised EQ-5D health state classifications. 
Finally, an algorithm for computing the utility index was performed from the model 
output. Results: 248 mexican patients were evaluated in the model: 54% were male 
and 46% were female; also 74.2% had low severity, 18.5% had moderate severity and 
7.3% had advanced severity; in addition, 16.5% of pacientes hadn´t formal education 
compared to 21% of patients having college or higher education. Finally, 60.1% of 
patients were 60 years old or more when the retrospective study was performed. 
Our model for the EQ-5D included ordinal terms to capture the effect of departures 
from perfect health as well as interaction effects. After fitting the model, the utility 
index for Parkinson´s disease reported was 0.8694. ConClusions: The model best 
predicts the values for observed health states. The resulting preference estimates 
represent a significant enhancement of the EQ-5D’s utility for health status assess-
ment and economic analysis in Parkinson´s disease for mexican patients.
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objeCtives: To examine health status, health care resource use, work productivity, 
and associated costs for patients with restless legs syndrome (RLS) compared to a 
control cohort and the association between these variables and increased symptom 
severity. Methods: The sample was drawn from the 2012 National Health and 
Wellness Survey (NHWS; n = 71,157) an annual survey of US adults. Respondents 
reporting a diagnosis of RLS (n = 2,392; 56.9% women, Mean age 55.9 years) were 
propensity score matched on demographics to an equally-sized non-diagnosed 
comparison group. Patients self-reported RLS symptom severity (mild, moderate, 
severe), health care resource use and work productivity. Costs of health care use 
and work productivity loss were extrapolated from existing governmental estimates 
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were 32.3%, 22.0%, 13.9%, and 13.0%, respectively. These rates were similar to those 
in non-responders. Respondents with PBA symptoms (CNS-LS≥ 13) reported signifi-
cantly poorer HRQOL in all EQ-5D domains. Mean scores were worse for anxiety/
depression, pain/discomfort, and usual activities; 85% reported at least moderate 
pain or anxiety/depression; 50% reported at least moderate problems with usual 
activities. ConClusions: PBA symptoms assessed by either CNS-LS or the “invol-
untary episodes” question are prevalent among Veterans with TBI who responded 
to the survey. PBA symptoms were correlated with worse HRQOL.
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objeCtives: Electronic Patient Reported Outcomes (ePRO) such as daily diaries 
are often used in migraine clinical trials to collect information regarding migraine 
frequency, duration, severity, and symptoms. In general, alarms are an effective 
tool for prompting subjects to complete diaries on schedule. However, 70-80% of 
migraineurs suffer from phonophobia during a migraine. Thus, it is possible that 
an alarm may worsen symptoms. To address this, a decibel meter was used to 
measure the sound level of alarms on three models of the PHT LogPad handheld 
electronic device, and readings were compared to published sound aversion thresh-
olds (SAT) for migraineurs. Methods: The LogPad (LW, CV and LV) models were 
placed at a distance of one or five feet from the decibel meter. Alarm sound was 
measured on two devices in triplicate at each sound setting. Results: The SAT 
for migraineurs is reported to be approximately 76 decibels (db) (ictal) and 91 db 
(interictal). Healthy subjects have a SAT of 105 db. When the LogPad LW and decibel 
meter were placed one foot apart, the decibel meter measured 58, 67, 75, and 83 
db at the normal, medium, high and very high sound settings, respectively, and 
measured 76 db for the CV and 80 db for the LV models. When any LogPad model 
was placed five feet away from the decibel meter, all readings were below the ictal 
SAT for migraineurs. ConClusions: Even at a 1 foot distance, the alarm volume 
on the LogPad LW can be set below the ictal SAT for migraineurs and is also above 
background sound. At a distance of 5 feet, all models tested are below SAT and 
above background. Therefore, the LogPad is a suitable handheld electronic device 
to use with migraineurs that suffer from phonophobia with alarm volumes that 
can be used below SAT.
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objeCtives: To describe the frequency and nature of patient-reported out-
come (PRO) conversations between physicians and patients with Cystic 
Fibrosis. Methods: A random sample of de-identified patients with Cystic 
Fibrosis in the United States was selected from a large de-identified database 
of medical office visit transcriptions. Transcriptions were based on physician-
dictated voice recordings detailing every individual patient encounter/visit. 
De-identified medical visit transcriptions were analyzed to evaluate the burden 
associated with Cystic Fibrosis, as depicted by PRO topics observed in patient-
physician dialog in the real-world practice setting. Descriptive statistics are 
reported. Results: 333 transcriptions of medical encounters between 130 phy-
sicians (most commonly pediatricians 11%, internists 10%, pulmonologists 8%, 
general practitioners 8%, and surgeons 8%) and 183 patients over a 2-year period 
were evaluated (patient mean age: 31yrs; 27% < 18yrs, male: 55%). Non-symptom 
related PROs, including quality of life and psychosocial impacts, were discussed 
by 50 patients (27%) (10% of patients < 18yrs, 34% of patients ≥ 18yrs); the most 
commonly reported concerns were related to anxiety (n= 16(9%)), depression 
(n= 14(8%)), ability to perform daily activities (n= 7(4%)), and work/school productiv-
ity (n= 6(3%)). Symptom-related PROs were discussed by 108 patients (59%) (52% of 
patients < 18yrs, 62% of patients ≥ 18yrs); the most commonly reported symptoms 
were cough (n= 51(28%)), difficulty breathing (n= 25(14%)), and difficulty gaining/
maintaining weight (n= 15(8%)). ConClusions: PROs, as a function of disease 
burden, were routinely discussed by patients with Cystic Fibrosis. PRO discussions 
were observed more frequently among adult patients than the pediatric patients, 
and symptom-related PROs were discussed more frequently than PROs related to 
quality of life and psychosocial impacts. Modalities to alleviate this patient burden, 
including appropriate therapeutic interventions, warrant scrutiny.
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objeCtives: The objectives of this study were to assess the quality of life and 
the determinants affecting QoL in children with epilepsy using Pediatric quality 
of life questionnaire (PedsQL). Methods: A prospective observational study was 
conducted at a public hospital. In these study children less than 18 years of age, 
diagnosed with epilepsy were included. HRQoL was assessed using PedsQL, which 
comprised of 23 questions related to physical, emotional, social and school func-
tioning. After getting consent, scale was administered to both parents and subjects 
separately. Multivariate logistic regression was done to assess the potential deter-
minants of low HRQoL scores. Results: A total of 270 children with epilepsy were 
included in this study. Mean age and mean duration of antiepileptic drug treat-
ment was found to be 11.2 years and 21.6±12 months respectively. Mean total score 
according to PedsQL was found to be 89.6±6.7 (Psychological subscale score 84.7±1.2, 
physical subscale score 94.4±5.9, emotional subscale score 85.6±16, social subscale 
score 94.7±9.9 and school subscale score 73.9±12.5). Long duration of antiepileptic 
objeCtives: Huntington’s disease (HD) is a rare neurodegenerative disease lead-
ing to sustained disability for patients and poor quality of life (QoL) for patients as 
well as caregivers. This study, conducted in US as a part of an international sur-
vey, investigated a disease-specific QoL instrument, the HD QoL Battery for Carers 
(HDQoL-C). Methods: The shortened version of the HDQoL-C comprised two 
components: the satisfaction with life (3 items) and the feelings about living with 
HD (17 items). Caregivers were asked to answer socio-demographic questions and 
complete the short version of the (HDQoL-C), a previously validated questionnaire. 
Item response could be chosen among 10 possibilities depending on frequency 
or intensity. Internal validity was evaluated through the factorial structure and 
internal consistency. External validation was tested using known-group compari-
son analyses between three severity subgroups (low, moderate, high), according 
to dependence, global clinical severity and motor severity. Results: The sample 
was composed of 361 family carers from US with 76% female, 16% single and 51 of 
average age. The majority of the caregivers represented the main caregivers of the 
HD patient (73%) and 61% of them lived with the HD patient. There were 2 items 
out of 20 with potential floor effects and 3 items with ceiling effects. Cronbach’s 
alpha coefficients ranged from 0.68 to 0.90 in the whole sample, indicating high 
internal consistency Analyses of the component of HDQoL-C dealing with the feel-
ings about living with HD, demonstrated satisfactory factor analysis. Known group 
analyses showed that the HDQoL-C scores were higher for carers who cared for 
patients in the low severity group than the two other groups, meaning that these 
carers had better QoL. ConClusions: The US shortened version of the HDQoL-C 
demonstrated good internal consistency and congruent validity when compared 
to the original English version.
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objeCtives: To examine seizure severity across treatment arms among clinical 
trial subjects with refractory partial-onset seizures (POS) who participated in a 
phase III clinical trial of eslicarbazepine acetate, a novel once-daily anticonvulsant 
recently approved for the adjunctive treatment of POS in adults. Methods: The 
Seizure Severity Questionnaire (SSQ), a validated instrument developed to evaluate 
the severity and bothersomeness of specific seizure characteristics, was adminis-
tered. The SSQ total score (TS) and domain scores of frequency and helpfulness of 
warning signs before seizures (BS), severity and bothersomeness of ictal movement 
and altered consciousness during seizures (DS), cognitive, emotional, and physical 
aspects of postictal recovery after seizures (AS), and overall severity and bother 
(SB) were calculated at baseline and at the end of maintenance therapy (12-week 
duration) from the per-protocol population. ANCOVA models, adjusted for baseline 
scores, estimated least square mean (LSM) differences between arms at the end of 
therapy. Results: Among 547 subjects, average age: 38.4, 63.3% Caucasian, 50.8% 
female, 70.4% (385) had TS results at baseline and at end-of-therapy. Among subjects 
receiving 1200 mg ESL, the TS LSM was significantly lower compared to placebo (2.80 
versus 3.29, p= 0.002); the LSMs were also significantly lower for DS (3.29 versus 
3.70, p= 0.032), AS (1.95 versus 2.51, p= 0.019), and SB (3.09 versus 3.65, p< 0.001), 
but not for BS. Among subjects treated with 800 mg ESL, the LSM differences vs. 
placebo for BS, DS, AS and TS did not achieve statistical significance. The SB LSM 
was significantly lower (3.28 versus 3.65, p= 0.013). ConClusions: In this post-
hoc analysis of a phase III trial, ESL-treated subjects had statistically-significantly 
lower SSQ total scores (1200 mg), less severity and bother during seizures (1200 mg), 
less cognitive, emotional and physical impact during postictal recovery (1200 mg), 
and lower overall levels of seizure severity and bother (1200 mg and 800 mg) than 
placebo-treated subjects.
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bACkgRound: PBA, characterized by uncontrollable episodes of crying and/or 
laughing, often exaggerated or inappropriate to the mood state, can occur in per-
sons with neurological disorders or injury of the brain. objeCtives: Compare PBA 
survey instruments and estimate prevalence of PBA symptoms and health-related 
quality of life (HRQOL) burden in Veterans with TBI. Methods: Cross-sectional 
survey with patient-level linkage to VA clinical data. OEF/OIF Veterans screening 
positive for TBI were mailed the seven-item Center for Neurologic Study-Lability 
Scale (CNS-LS) questionnaire with an initial question asking if the Veteran had 
“involuntary episodes of crying and/or laughing that were exaggerated or even 
contrary to how they felt at the time”. The EQ-5D, a standardized HRQOL ques-
tionnaire, was included. The presence of PBA symptoms was defined in this study 
as CNS-LS score≥ 13. The sensitivity of the “involuntary episodes” question was 
assessed against the CNS-LS. Results: The 4400 Veterans mailed surveys were 
predominantly male (95%); mean(SD) age 34(8.8) years. 728 Veterans returned sur-
veys. Among respondents, 60% answered “yes” to the “involuntary episodes” ques-
tion and 70% had CNS-LS≥ 13 (PBA symptoms). The ROC curve for the ‘involuntary 
episodes’ question indicates optimal sensitivity/specificity at CNS-LS score of 12. 
Comorbidities diagnosed in the CNS-LS≥ 13 population included: PTSD (53.4%), 
major depression (34.5%), headaches/migraine (20.0%) and anxiety disorders (20.4%); 
in contrast, prevalence for the same comorbidities among Veterans with CNS-LS< 13 
